REGENERON PHARMACEUTICALS, INC. Inventory, Finished Goods, Net of Reserves
REGENERON PHARMACEUTICALS, INC. (REGN) had Inventory, Finished Goods, Net of Reserves of $142.00 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Notes › Inventory, Net, Items Net of Reserve Alternative › Inventory, Finished Goods and Work in Process, Net of Reserves
us-gaap:InventoryFinishedGoodsNetOfReserves · last filed 2026-07-30
- 2026-06-30: Inventory, Finished Goods, Net of Reserves $142.00M.
- 2026-03-31: Inventory, Finished Goods, Net of Reserves $160.50M.
- 2025-12-31: Inventory, Finished Goods, Net of Reserves $190.20M.
- 2025-09-30: Inventory, Finished Goods, Net of Reserves $169.70M.
| Period end | Inventory, Finished Goods, Net of Reserves | Inventory, Finished Goods, Net of Reserves as first filed |
|---|---|---|
| 2026-06-30 | $142.00M 10-Q · filed 2026-07-30 | |
| 2026-03-31 | $160.50M 10-Q · filed 2026-04-29 | |
| 2025-12-31 | $190.20M 10-Q · filed 2026-07-30 | |
| 2025-09-30 | $169.70M 10-Q · filed 2025-10-28 | |
| 2025-06-30 | $144.40M 10-Q · filed 2025-08-01 | |
| 2025-03-31 | $110.00M 10-Q · filed 2025-04-29 | |
| 2024-12-31 | $139.80M 10-K · filed 2026-02-04 | |
| 2024-09-30 | $164.60M 10-Q · filed 2024-10-31 | |
| 2024-06-30 | $154.40M 10-Q · filed 2024-08-01 | |
| 2024-03-31 | $180.50M 10-Q · filed 2024-05-02 | |
| 2023-12-31 | $147.30M 10-K · filed 2025-02-05 | |
| 2023-09-30 | $114.20M 10-Q · filed 2023-11-02 | |
| 2023-06-30 | $125.30M 10-Q · filed 2023-08-03 | |
| 2023-03-31 | $169.30M 10-Q · filed 2023-05-04 | |
| 2022-12-31 | $98.60M 10-K · filed 2024-02-05 | |
| 2022-09-30 | $65.00M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $45.60M 10-Q · filed 2022-08-03 | |
| 2022-03-31 | $47.30M 10-Q · filed 2022-05-04 | |
| 2021-12-31 | $73.70M 10-K · filed 2023-02-06 | |
| 2021-09-30 | $60.10M 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $106.30M 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $117.90M 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $121.70M 10-K · filed 2022-02-07 | |
| 2020-09-30 | $132.10M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $132.00M 10-Q · filed 2020-08-05 | |
| 2020-03-31 | $96.40M 10-Q · filed 2020-05-05 | |
| 2019-12-31 | $70.60M 10-K · filed 2021-02-08 | |
| 2019-09-30 | $49.40M 10-Q · filed 2019-11-05 | |
| 2019-06-30 | $34.10M 10-Q · filed 2019-08-06 | |
| 2019-03-31 | $30.80M 10-Q · filed 2019-05-07 | |
| 2018-12-31 | $24.40M 10-K · filed 2020-02-07 | |
| 2018-09-30 | $28.40M 10-Q · filed 2018-11-06 | |
| 2018-06-30 | $26.57M 10-Q · filed 2018-08-02 | |
| 2018-03-31 | $22.85M 10-Q · filed 2018-05-03 | |
| 2017-12-31 | $21.80M 10-K · filed 2019-02-07 | $21.79M 10-K · filed 2018-02-08 |
| 2017-09-30 | $23.96M 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $33.02M 10-Q · filed 2017-08-03 | |
| 2017-03-31 | $20.26M 10-Q · filed 2017-05-04 | |
| 2016-12-31 | $13.33M 10-K · filed 2018-02-08 | |
| 2016-09-30 | $16.98M 10-Q · filed 2016-11-04 | |
| 2016-06-30 | $14.42M 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $14.23M 10-Q · filed 2016-05-05 | |
| 2015-12-31 | $11.20M 10-K · filed 2017-02-09 | |
| 2015-09-30 | $12.51M 10-Q · filed 2015-11-04 | |
| 2015-06-30 | $9.49M 10-Q · filed 2015-08-04 | |
| 2015-03-31 | $11.40M 10-Q · filed 2015-05-07 | |
| 2014-12-31 | $10.77M 10-K · filed 2016-02-11 | |
| 2014-09-30 | $11.37M 10-Q · filed 2014-11-04 | |
| 2014-06-30 | $12.21M 10-Q · filed 2014-08-05 | |
| 2014-03-31 | $13.23M 10-Q · filed 2014-05-08 | |
| 2013-12-31 | $14.35M 10-K · filed 2015-02-12 | |
| 2013-09-30 | $12.32M 10-Q · filed 2013-11-05 | |
| 2013-06-30 | $10.43M 10-Q · filed 2013-08-06 | |
| 2013-03-31 | $6.39M 10-Q · filed 2013-05-03 | |
| 2012-12-31 | $2.57M 10-K · filed 2014-02-13 | |
| 2011-12-31 | $1.14M 10-K · filed 2013-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |